VI-1121 for the Treatment Alzheimer's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and effective as a daily treatment for Alzheimer's disease that is worsening despite current treatment.

Key facts

Study ID

NCT01428362

Run by

VIVUS LLC

People needed

61

Starts

2011-08-01

Expected to finish

2013-08-01

Last updated by the study team

2013-12-11

Who can join

Age: 60 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• clinical diagnosis of Alzheimer's disease
• CT or MRI within 2 years prior to study
• stable dose of current Alzheimer's treatment for at least 3 months

You may not qualify if…

• advanced, severe, progressive or unstable disease
• history of cerebrovascular disease or myocardial infarction within 6 months

Where it is running

• Study site — San Francisco, California, United States
• Study site — Santa Monica, California, United States
• Study site — Sunrise, Florida, United States
• Study site — Louisville, Kentucky, United States
• Study site — Las Vegas, Nevada, United States
• Study site — Toms River, New Jersey, United States
• Study site — New Windsor, New York, United States
• Study site — Durham, North Carolina, United States
• Study site — Raleigh, North Carolina, United States
• Study site — Toledo, Ohio, United States
• Study site — Plano, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.